Novartis India will acquire the Minipress and Minipres trademarks and related intellectual property from Pfizer for about ₹1,250 crore. Minipress XL, used for hypertension and benign prostatic hyperplasia, generated ₹228.6 crore in revenue as of July 2026, according to IQVIA data.

Novartis India Ltd on Monday announced that its Board of Directors has approved the acquisition of the trademarks 'Minipress' and 'Minipres' from Pfizer Inc. USA and Pfizer…

Novartis India will acquire the Minipress and Minipres trademarks and related intellectual property from Pfizer for about ₹1,250 crore. Minipress XL, used for hypertension and…